{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:39:20Z","timestamp":1764571160982,"version":"3.37.3"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-16-12430"],"award-info":[{"award-number":["ESR-16-12430"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jacig.2024.100310","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T23:53:54Z","timestamp":1721692434000},"page":"100310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis"],"prefix":"10.1016","volume":"3","author":[{"given":"Christiane E.","family":"Whetstone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth P.","family":"Cusack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Howie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catie","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhuha","family":"Al-Sajee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Beaudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Wattie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Alsaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbey","family":"Schlatman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Luk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Inman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roma","family":"Sehmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermenio","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-2385","authenticated-orcid":false,"given":"Gail M.","family":"Gauvreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2024.100310_bib1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2024.100310_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","article-title":"IgE, mast cells, and eosinophils in atopic dermatitis","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","article-title":"Biology of the eosinophil","volume":"101","author":"Blanchard","year":"2009","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0091-6749(99)70069-2","article-title":"Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm","volume":"104","author":"Wardlaw","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000058788","article-title":"Differentiation of human eosinophils","volume":"76","author":"Sehmi","year":"2000","journal-title":"Human Eosinophils"},{"key":"10.1016\/j.jacig.2024.100310_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2024.100310_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.12.160","article-title":"Prednisolone treatment reduces type 2 inflammation in skin lesions of patients with atopic dermatitis","volume":"147","author":"Price","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2024.100310_bib10","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2024.100310_bib11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.06.002","article-title":"Eosinophil-related disease and the skin","volume":"6","author":"Leiferman","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100310_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12016-012-8326-y","article-title":"Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema","volume":"45","author":"Altman","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/exd.13782","article-title":"Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes","volume":"27","author":"Amber","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jacig.2024.100310_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib15","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0006-291X(87)80293-0","article-title":"Selective localization of vasoactive intestinal peptide and substance P in human eosinophils","volume":"148","author":"Aliakbari","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacig.2024.100310_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s004030000142","article-title":"Eosinophil cationic protein-and eosinophil-derived neurotoxin\/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis","volume":"292","author":"Johansson","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jacig.2024.100310_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaci.2014.07.003","article-title":"Eosinophil-dependent skin innervation and itching following contact toxicant exposure in mice","volume":"135","author":"Lee","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib18","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.4049\/jimmunol.149.10.3309","article-title":"Neuropeptides modulate human eosinophil chemotaxis","volume":"149","author":"Numao","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib19","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.4049\/jimmunol.145.8.2581","article-title":"Characterization of eosinophil cell activation by peptides. Differential effects of substance P, melittin, and FMET-Leu-Phe","volume":"145","author":"Kroegel","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib20","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.0022-202X.2004.22619.x","article-title":"Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin","volume":"122","author":"Phipps","year":"2004","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jacig.2024.100310_bib21","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway\u00a0hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2024.100310_bib22","doi-asserted-by":"crossref","first-page":"AB157","DOI":"10.1016\/j.jaci.2020.12.563","article-title":"The effect of benralizumab on allergen-induced responses in subjects with mild allergic asthma","volume":"147","author":"Gauvreau","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/0190-9622(91)70166-Y","article-title":"A current perspective on the role of eosinophils in dermatologic diseases","volume":"24","author":"Leiferman","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jacig.2024.100310_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1056\/NEJM198508013130502","article-title":"Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis","volume":"313","author":"Leiferman","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2024.100310_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0091-6749(03)01798-6","article-title":"Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge","volume":"112","author":"Liu","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib26","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.4049\/jimmunol.169.11.6452","article-title":"Decreased expression of membrane IL-5 receptor \u03b1 on human eosinophils: I. Loss of membrane IL-5 receptor \u03b1 on airway eosinophils and increased soluble IL-5 receptor \u03b1 in the airway after allergen challenge","volume":"169","author":"Liu","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti\u2013interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2024.100310_bib28","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2024.100310_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2222.2012.04065.x","article-title":"Anti-IL-5 attenuates activation and surface density of \u03b22-integrins on circulating\u00a0eosinophils after segmental antigen challenge","volume":"43","author":"Johansson","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2024.100310_bib30","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.4049\/jimmunol.162.5.2477","article-title":"Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells","volume":"162","author":"Li","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1067\/mai.2001.118600","article-title":"IL-13 induces eosinophil recruitment into the lung by an IL-5\u2013and eotaxin-dependent mechanism","volume":"108","author":"Pope","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.5414\/CP202446","article-title":"Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab","volume":"53","author":"Pouliquen","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jacig.2024.100310_bib33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/cpdd.205","article-title":"Pharmacokinetics and pharmacodynamics of mepolizumab, an anti\u2013interleukin 5 monoclonal antibody, in healthy Japanese male subjects","volume":"5","author":"Tsukamoto","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jacig.2024.100310_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti\u2013IL-5 antibody SCH55700","volume":"114","author":"Kim","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib37","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti\u2013IL-5 receptor \u03b1 mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib38","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1172\/JCI119789","article-title":"Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A\u00a0novel marker of progenitor cell commitment towards eosinophilic differentiation","volume":"100","author":"Sehmi","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacig.2024.100310_bib39","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/jid.2009.358","article-title":"The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation","volume":"130","author":"Cowden","year":"2010","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jacig.2024.100310_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jaci.2023.03.023","article-title":"Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice","volume":"152","author":"LeSuer","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100310_bib41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/resp.14506","article-title":"Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics","volume":"28","author":"Malik","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.jacig.2024.100310_bib42","first-page":"e1211","article-title":"Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial","volume":"37","author":"Guttman-Yassky","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jacig.2024.100310_bib43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jaci.2022.08.009","article-title":"Biologics for allergic and immunologic diseases","volume":"150","author":"Morita","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T17:49:08Z","timestamp":1731347348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829324001061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2772829324001061"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100310","relation":{},"ISSN":["2772-8293"],"issn-type":[{"type":"print","value":"2772-8293"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100310"}}